PA
SGMO

Parallel Advisors’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Parallel Advisors’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,630
Closed -$2.87K – 3503
2023
Q1 		$2.87K Buy
1,630
+1,174
+257% +$3.35K ﹤0.01% 2623
2022
Q4 		$1.43K Buy
+456
New +$1.77K ﹤0.01% 2804
2022
Q1 		– Sell
-118
Closed -$1K – 3244
2021
Q4 		$1K Sell
118
-266
-69% -$2.31K ﹤0.01% 2954
2021
Q3 		$3K Buy
384
+266
+225% +$2.63K ﹤0.01% 2597
2021
Q2 		$1K Hold
118
– – ﹤0.01% 2822
2021
Q1 		$1K Hold
118
– – ﹤0.01% 2689
2020
Q4 		$2K Hold
118
– – ﹤0.01% 2347
2020
Q3 		$1K Hold
118
– – ﹤0.01% 2486
2020
Q2 		$1K Hold
118
– – ﹤0.01% 2366
2020
Q1 		$0 Buy
+118
New +$876 ﹤0.01% 2618

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMU
Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Parallel Advisors's SGMO Position: Q2 2023 in Review

Parallel Advisors sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2023, closing a stake of 1,630 shares — an estimated $2.87K sold.

Parallel Advisors first reported a position in SGMO in Q1 2020 and held it in 10 quarters. The position peaked at $3K in Q3 2021. 152 funds tracked by Wall St. Rank hold SGMO as of Q2 2023.

  • Parallel Advisors reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2023 after selling out during the quarter.
  • Parallel Advisors sold 1,630 SANGAMO THERAPEUTICS INC shares in Q2 2023, an estimated $2.87K.
  • Parallel Advisors first reported a position in SANGAMO THERAPEUTICS INC in Q1 2020 and held it in 10 quarters.
  • Parallel Advisors's SANGAMO THERAPEUTICS INC position peaked at $3K in Q3 2021.
  • 152 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2023.

Based on Parallel Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.